

Title (en)
RECEPTOR SELECTIVE RETINOID AND REXINOID COMPOUNDS AND IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY

Title (de)
REZEPTORSELEKTIVE RETINOID- UND REXINOIDVERBINDUNGEN UND IMMUNMODULATOREN ZUR KREBSIMMUNOTHERAPIE

Title (fr)
COMPOSÉS RÉTINOÏDES ET REXINOÏDES SÉLECTIFS DU RÉCEPTEUR ET MODULATEURS IMMUNITAIRES POUR L'IMMUNOTHÉRAPIE DU CANCER

Publication
EP 3468600 A4 20191113 (EN)

Application
EP 17811125 A 20170609

Priority
• US 201662348646 P 20160610
• US 201662406779 P 20161011
• US 2017036870 W 20170609

Abstract (en)
[origin: US2017354623A1] Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.

IPC 8 full level
A61K 39/395 (2006.01); **A61K 31/192** (2006.01); **A61K 31/352** (2006.01); **A61K 31/382** (2006.01); **A61K 31/505** (2006.01); **A61K 31/5513** (2006.01); **A61K 45/06** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01); **C07K 16/30** (2006.01)

CPC (source: EP IL KR US)
A61K 31/192 (2013.01 - EP IL KR US); **A61K 31/196** (2013.01 - IL KR US); **A61K 31/352** (2013.01 - EP IL KR US); **A61K 31/382** (2013.01 - EP IL KR US); **A61K 31/4436** (2013.01 - KR); **A61K 31/505** (2013.01 - EP IL KR US); **A61K 31/5513** (2013.01 - EP IL KR US); **A61K 39/39541** (2013.01 - EP IL KR US); **A61K 39/3955** (2013.01 - IL KR US); **A61K 45/06** (2013.01 - EP IL KR US); **A61P 35/00** (2018.01 - EP KR US); **C07K 16/2818** (2013.01 - EP IL KR US); **C07K 16/30** (2013.01 - IL); **A61K 2039/505** (2013.01 - IL KR US); **A61K 2300/00** (2013.01 - IL KR); **C07K 2317/76** (2013.01 - EP IL KR US)

C-Set (source: EP US)
1. **A61K 31/352 + A61K 2300/00**
2. **A61K 31/192 + A61K 2300/00**
3. **A61K 31/382 + A61K 2300/00**
4. **A61K 31/5513 + A61K 2300/00**
5. **A61K 31/505 + A61K 2300/00**
6. **A61K 39/39541 + A61K 2300/00**

Citation (search report)
• [Y] WO 2016015095 A1 20160204 - UNIV WESTERN AUSTRALIA [AU], et al
• [XPYI] WO 2016144976 A1 20160915 - KING S COLLEGE LONDON [GB], et al
• See also references of WO 2017214575A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
US 2017354623 A1 20171214; US 9907768 B2 20180306; AU 2017278220 A1 20181206; AU 2017278220 B2 20220721; AU 2017278220 C1 20221013; AU 2022256117 A1 20221117; CA 3026563 A1 20171214; CA 3026563 C 20231128; CN 109310763 A 20190205; CN 109310763 B 20221021; CN 115671292 A 20230203; EP 3468600 A1 20190417; EP 3468600 A4 20191113; IL 263629 A 20190131; IL 263629 B 20221001; IL 263629 B2 20230201; JP 2019517557 A 20190624; KR 20190017950 A 20190220; MX 2018015352 A 20190328; SG 11201810951R A 20190130; US 10004708 B2 20180626; US 10004709 B2 20180626; US 10123982 B2 20181113; US 11648223 B2 20230516; US 2018133179 A1 20180517; US 2018133180 A1 20180517; US 2018133181 A1 20180517; US 2018133182 A1 20180517; US 2018133183 A1 20180517; US 2018338941 A1 20181129; US 2019105292 A1 20190411; US 2021275478 A1 20210909; US 2022184012 A1 20220616; WO 2017214575 A1 20171214; ZA 201807809 B 20190828

DOCDB simple family (application)
US 201715620411 A 20170612; AU 2017278220 A 20170609; AU 2022256117 A 20221019; CA 3026563 A 20170609; CN 201780035846 A 20170609; CN 202211285002 A 20170609; EP 17811125 A 20170609; IL 26362918 A 20181210; JP 2018564359 A 20170609; KR 20197000997 A 20170609; MX 2018015352 A 20170609; SG 11201810951R A 20170609; US 2017036870 W 20170609; US 201815868391 A 20180111; US 201815868432 A 20180111; US 201815868450 A 20180111; US 201815868459 A 20180111; US 201815868469 A 20180111; US 201816050441 A 20180731; US 201816211045 A 20181205; US 202117213579 A 20210326; US 202217685626 A 20220303; ZA 201807809 A 20181120